Argenx SE stock (NL0010832176): FMR LLC boosts stake amid price gains

FMR LLC recently increased its stake in Argenx SE, a biotech focused on autoimmune therapies, as the stock rose 1.93% to €698.20 on Euronext Brussels.

Argenx SE attracted investor attention after FMR LLC acquired additional shares, according to a recent filing reported by ad-hoc-news.de as of May 2026. The stock gained 1.93% to €698.20 on Euronext Brussels, per live exchange data. Argenx also presented at the Bank of America Global Healthcare Conference, discussing leadership and pipeline updates.

As of: 14.05.2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: Argenx SE
• Sector/industry: Biopharmaceuticals
• Headquarters/country: Netherlands
• Core markets: US, Europe
• Key revenue drivers: Vyvgart sales
• Home exchange/listing venue: Euronext Brussels (ARGX), Nasdaq (ARGX)
• Trading currency: EUR, USD

Argenx SE: core business model

Argenx SE develops antibody therapies targeting rare autoimmune diseases using its proprietary Simple Antibody platform. The lead product, Vyvgart (efgartigimod), treats generalized myasthenia gravis (gMG) and is approved in the US and Europe. The company leverages Fc engineering to enhance antibody efficacy, focusing on diseases with high unmet needs.

Main revenue and product drivers for Argenx SE

Vyvgart drives the majority of revenue, with strong US sales contributing significantly for American investors via the Nasdaq ADR listing. Argenx reported robust uptake in gMG patients, supported by real-world evidence. The pipeline includes empasiprubart for multifocal motor neuropathy and other immunology indications.

Why Argenx SE matters for US investors

Argenx SE's Nasdaq ADR (ARGX) provides US investors direct access to its growth in autoimmune therapies, with Vyvgart's US market approval driving key revenue. The company's exposure to the expanding US immunology sector underscores its relevance amid rising demand for targeted biologics.

Conclusion

FMR LLC's stake increase and the recent 1.93% price gain on Euronext reflect sustained interest in Argenx SE's antibody platform and Vyvgart commercialization. Pipeline advancements and conference presentations signal ongoing momentum. Investors track regulatory progress and sales data for future developments.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.